Search

The integration of artificial intelligence (AI) into healthcare systems marked a pivotal evolution in clinical analytics architectures and governance structures, transforming data-driven decision-making from siloed, retrospective analyses to dynamic, predictive, and integrated frameworks. This period witnessed rapid advancements in machine learning (ML) applications for healthcare infrastructure, encompassing electronic health records (EHRs), imaging diagnostics, population health management, and real-time monitoring systems. Key developments included the shift toward federated learning to address data privacy concerns, the emergence of explainable AI (XAI) to enhance clinical trustworthiness, and the standardization of regulatory pathways for AI as medical devices. Architecturally, healthcare systems evolved from static analytics pipelines—where data ingestion, model training, and inference occurred in isolated phases—to adaptive, closed-loop configurations that incorporate feedback mechanisms for continuous model refinement and human-AI collaboration. Governance structures are adapted accordingly, emphasizing ethical frameworks to mitigate bias, ensure data equity, and promote algorithmic accountability, particularly for underserved populations. This review synthesizes literature from this timeframe, highlighting how AI-enabled analytics architectures facilitated precision medicine by integrating multimodal data sources, such as genomics, wearables, and social determinants of health, into cohesive systems. Challenges in interoperability and scalability were addressed through consensus guidelines like CONSORT-AI and SPIRIT-AI, which promoted transparent reporting of AI interventions in clinical trials. Moreover, the COVID-19 pandemic accelerated AI deployment in pandemic response systems, underscoring the need for resilient architectures capable of handling real-time data surges and uncertainty communication. Governance evolved to include multi-stakeholder perspectives, from regulatory bodies such as the FDA to clinical practitioners, ensuring that AI tools align with evidence-based medicine. This narrative review provides an original systems-level framing, organizing the literature around data-to-decision cycles, infrastructural integration, and governance maturation. By examining cross-study insights, it reveals how AI has fostered intelligent healthcare ecosystems, reducing diagnostic bias across diverse cohorts and enhancing decision support without over-relying on black-box models. Ultimately, this synthesis underscores the transition from AI as a supplementary tool to a foundational element of healthcare systems, paving the way for equitable, efficient clinical analytics.

The integration of artificial intelligence (AI) into healthcare systems has transformed clinical analytics, particularly in improving medication safety through advanced reconciliation processes, structured error taxonomies, and careful deployment strategies. This narrative review examines how AI-driven analytics embedded within clinical infrastructures can reduce medication-related risks in hospital and ambulatory care settings. AI technologies such as natural language processing and machine learning enable automated detection of medication discrepancies by analyzing electronic health records and identifying inconsistencies that may be overlooked by manual review.AI systems also support the classification and prediction of medication errors, including prescribing mismatches and administration failures, allowing clinical decision support systems to identify high-risk prescriptions and support safer prescribing practices. In addition, AI contributes to closed-loop healthcare systems where analytics provide real-time decision support across the data lifecycle, from information ingestion to post-intervention feedback.Despite these benefits, several deployment constraints remain, including data quality limitations, interoperability challenges, and ethical concerns related to bias and governance. These factors highlight the importance of robust system design and transparent AI models to ensure safe and equitable implementation. Furthermore, AI can support standardized error taxonomies and pharmacovigilance through structured analytical frameworks that improve reporting and monitoring of adverse events.Overall, this review positions AI as a central component of adaptive clinical systems capable of strengthening medication safety. However, its effectiveness depends on addressing technical, operational, and regulatory barriers. Continued interdisciplinary collaboration will be essential to refine AI-enabled clinical analytics and support safer, more efficient healthcare systems.